Progress of drug resistance mechanism of ibrutinib / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
;
(12): 434-437, 2019.
Article
in Chinese
| WPRIM
| ID: wpr-751420
ABSTRACT
As a novel molecular targeted anti﹣tumor drug, it has been proved that ibrutinib has remarkable anti﹣tumor activity and is characterized by high efficiency and low toxicity. However, the risks of drug resistance, safety, and disease transformation are gradually concerned. This review focused on the research progress of ibrutinib′s drug resistance mechanism in various B﹣cell non﹣Hodgkin lymphomas.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Journal of Leukemia & Lymphoma
Year:
2019
Type:
Article
Similar
MEDLINE
...
LILACS
LIS